Silence Therapeutics (SLN) Cash & Equivalents (2018 - 2026)

Silence Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $5.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 91.28% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 91.28% YoY), while the FY2025 annual figure was $11.3 million, down 90.71% from the prior year.
• Cash & Equivalents came in at $5.7 million for Q1 2026 at Silence Therapeutics, down from $11.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $143.4 million in Q1 2024 to a low of $5.7 million in Q1 2026.
• A 5-year average of $72.0 million and a median of $67.1 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 271.57% in 2024 and sank 91.28% in 2026, its largest moves.
• Silence Therapeutics' Cash & Equivalents stood at $49.2 million in 2022, then jumped by 36.17% to $67.1 million in 2023, then surged by 80.93% to $121.3 million in 2024, then slumped by 90.71% to $11.3 million in 2025, then tumbled by 49.84% to $5.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $5.7 million, $11.3 million, and $82.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison